



Presentation March 2017



Disclaimer

The information in this presentation dated March 2017 is a snapshot and does not contain ALL information necessary to make an investment decision. It DOES NOT PUPORT TO BE A COMPLETE DESCRIPTION OF TRUSCREEN. THIS PRESENTATION IS NOT INVESTMENT ADVICE OR FINANCIAL ADVICE. IN MAKING AN INVESTMENT DECISION, INVESTORS MUST RELY ON THEIR OWN EXAMINATION OF TRUSCREEN, INCLUDING THE MERITS AND RISKS INVOLVED. INVESTORS SHOULD CONSULT WITH THEIR OWN LEGAL, TAX, BUSINESS AND/OR FINANCIAL ADVISORS.

THE INFORMATION CONTAINED IN THIS PRESENTATION HAS BEEN PREPARED IN GOOD FAITH BY TRUSCREEN. There can be no assurance that actual outcomes will not materially differ from the forward looking statements presented. A number of important factors could cause actual results or performance to differ materially from the forward-looking statements. The forward-looking statements are based on information available to TruScreen as at the date of this presentation. TruScreen, its advisers, affiliates, related bodies corporate, directors, officers, partners, employees and agents make no representation or warranty, express or implied, as to the currency, accuracy, reliability or completeness of information in this presentation. Except as required by law (including the NZAX Listing Rules), TruScreen undertakes no obligation to provide any additional or updated information whether as a result of new information, future events or results or otherwise.

TO THE MAXIMUM EXTENT PERMITTED BY LAW, TRUSCREEN, ITS DIRECTORS, OFFICERS, EMPLOYEES AND AGENTS DISCLAIM ALL LIABILITY AND RESPONSIBILITY (INCLUDING WITHOUT LIMITATION ANY LIABILITY ARISING FROM FAULT OR NEGLIGENCE ON THE PART OF TRUSCREEN, ITS DIRECTORS, OFFICERS, EMPLOYEES AND AGENTS) FOR ANY DIRECT OR INDIRECT LOSS OR DAMAGE WHICH MAY BE SUFFERED BY ANY RECIPIENT THROUGH USE OF OR RELIANCE ON ANYTHING CONTAINED IN, OR OMITTED FROM, THIS PRESENTATION.

This presentation is not a prospectus, investment statement or disclosure document, or an offer of shares for subscription, or sale, in any jurisdiction

Who We Are

- New Zealand listed company
- Key Asset: Opto-electric technology for the detection of cancerous tissue
- World's only certified, real time, primary Cervical Cancer screening technology

TruScreen Unique Positioning

The World's Only

- Real Time
- Proven and Certified
- Objective
- Optical & Electrical
- Cervical Cancer
- Primary Screening Device



Recent Technical Achievements

Hardware

- Entire new device
 - Wireless Handheld Device
 - Increased processing capacity
 - Improved performance via improved design & components
 - Browser connectivity

Software

- Significantly improved performance via new algorithm

Recent Commercial Achievements

1. CHINA

- Secured National KOL support
- Confirmed continuation of existing screening programs – mid 2017
- Further screening programs expected – mid 2017
- Approved to supply Chinese military hospitals
- Significant marketing and training programs completed countrywide
- Regulatory approval in process (CFDA expected mid 2017)

Recent Commercial Achievements

2. MEXICO

- Regulatory approval granted for TruScreen2
- Government evaluation commenced – mid 2017 decision
- KOL, technical & expert evaluation completed
- Clinical trial (real world) completed

| Mexico Real World Performance 2016 | | | |
|------------------------------------|-----------|-----|---------|
| | TruScreen | Pap | HPV DNA |
| Sensitivity | 78% | 36% | 56% |

Recent Commercial Achievements

3. EUROPE

- Regulatory certification granted (CE) for TruScreen2
- Established European sales and distribution hub from UK
- Significantly expanded distribution EU network
- Commercial sales commence 2017

Recent Commercial Achievements

4. INDIA

- Appointed Indian distribution partner – 700 employees
- Identified large scale government screening opportunity – late 2017-18
- Commenced engagement with Government of India
- Sales to private sector commence 2017
- World largest screening market of 300M women
- Proposing in – country manufacturing to supply government demand

Commercial Prospects

Mexico:

- Expect adoption in Government sponsored screening programmes – mid 2017
- Increased sales to private sector in 2017
- Propose expand distribution network into Latin America

China:

- Expect regulatory approval for TruScreen2 – mid 2017
- Participation in Government screening programs
- Increase sales to Military Hospitals
- Recommence sponsored screening programmes

Commercial Prospects

Europe:

- Initiate sales into new distribution channels
- Expand distribution network + 10 countries

India:

- Initiate sales to private sector
- Secure adoption in Government screening programs
- Establish in-country manufacturing facilities

Ongoing improvements to clinical performance:

- Clinical testing and release of upgraded software – mid 2017

Evaluate adaption of technology to other cancers

The world's only real time primary
screening device for cervical cancer

Thank You